Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma
The purpose of this study is to provide treatment for patients who have relapsed NHL or refractory NHL, and to determine the effectiveness and safety of the Zevalin and Rituxan regimens or Rituxan therapy alone on your disease.
Non-Hodgkin's Lymphoma
DRUG: Zevalin (ibritumomab tiuxetan)|DRUG: Rituxan (rituximab)
Event-free survival
overall response rate|complete response rate|unconfirmed complete response rate|partial response rate|duration of response|time to progression|time-to-next anticancer therapy|quality of life|overall survival|safety profile
The purpose of this study is to provide treatment for patients who have relapsed NHL or refractory NHL, and to determine the effectiveness and safety of the Zevalin and Rituxan regimens or Rituxan therapy alone on your disease.